Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced its participation in the Leerink 10th Annual Global Healthcare Conference. CEO Bruce Cozadd will present on February 24, 2021, at 1:40 p.m. EST. The presentation will include a business and financial update, accessible via a live audio webcast on the Jazz Pharmaceuticals website. An archive will be available for at least a week post-presentation. Jazz is focused on developing innovative medications in neuroscience and oncology, with a global presence serving patients in over 90 countries.
- CEO Bruce Cozadd will provide a significant business and financial update on February 24, 2021.
- Participation in a reputable healthcare conference enhances visibility and potential investor interest.
- None.
DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Leerink 10th Annual Global Healthcare Conference.
Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Wednesday, February 24, 2021 at 1:40 p.m. EST / 6:40 p.m. GMT.
A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
An archive of the webcast will be available following the presentation for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Jazz Pharmaceuticals Contacts: | |
Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations U.S. +1 561 306 4035 | Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Ireland +353 1 697 2141 U.S. +1 215 867 4910 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-participation-in-the-leerink-10th-annual-global-healthcare-conference-301230162.html
SOURCE Jazz Pharmaceuticals plc
FAQ
What is the date of Jazz Pharmaceuticals' presentation at the Leerink Healthcare Conference?
Who will present Jazz Pharmaceuticals' updates at the conference?
How can I access the webcast of the Jazz Pharmaceuticals presentation?
Will there be an archive of the Jazz Pharmaceuticals presentation available?
What are the main therapeutic areas focused on by Jazz Pharmaceuticals?
